Several genetic abnormalities have been identified in ICC, including alterations such as TP53, ARID1A, and KRAS, though specifically FGFR and IDH seem to be quite promising in the pursuit of specific therapeutic targets for ICC [74,75,76]. This evidence concerns the gene KRAS and intrahepatic cholangiocarcinoma.